Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 95

1.

Protein interaction screening identifies SH3RF1 as a new regulator of FAT1 protein levels.

de Bock CE, Hughes MR, Snyder K, Alley S, Sadeqzadeh E, Dun MD, McNagny KM, Molloy TJ, Hondermarck H, Thorne RF.

FEBS Lett. 2017 Jan 27. doi: 10.1002/1873-3468.12569. [Epub ahead of print]

PMID:
28129444
2.

Scout-MRM: Multiplexed Targeted Mass Spectrometry-Based Assay without Retention Time Scheduling Exemplified by Dickeya dadantii Proteomic Analysis during Plant Infection.

Rougemont B, Bontemps Gallo S, Ayciriex S, Carrière R, Hondermarck H, Lacroix JM, Le Blanc JC, Lemoine J.

Anal Chem. 2017 Feb 7;89(3):1421-1426. doi: 10.1021/acs.analchem.6b03201.

PMID:
28029036
3.

Albumin hybrid nanoparticles loaded with tyrosine kinase A inhibitor GNF-5837 for targeted inhibition of breast cancer cell growth and invasion.

Shargh VH, Hondermarck H, Liang M.

Int J Pharm. 2016 Dec 30;515(1-2):527-534. doi: 10.1016/j.ijpharm.2016.10.057.

PMID:
27793712
4.

Deficiency in Outer Dense Fiber 1 Is a Marker and Potential Driver of Idiopathic Male Infertility.

Hetherington L, Schneider EK, DeKretser D, Muller CH, Hondermarck H, Velkov T, Baker MA.

Mol Cell Proteomics. 2016 Dec;15(12):3685-3693.

PMID:
27770032
5.

ProNGF is a potential diagnostic biomarker for thyroid cancer.

Faulkner S, Roselli S, Demont Y, Pundavela J, Choquet G, Leissner P, Oldmeadow C, Attia J, Walker MM, Hondermarck H.

Oncotarget. 2016 May 10;7(19):28488-97. doi: 10.18632/oncotarget.8652.

6.

Antibody-targeted biodegradable nanoparticles for cancer therapy.

Shargh VH, Hondermarck H, Liang M.

Nanomedicine (Lond). 2016 Jan;11(1):63-79. doi: 10.2217/nnm.15.186. Review.

PMID:
26654068
7.

INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas.

Chi MN, Guo ST, Wilmott JS, Guo XY, Yan XG, Wang CY, Liu XY, Jin L, Tseng HY, Liu T, Croft A, Hondermarck H, Scolyer RA, Jiang CC, Zhang XD.

Oncotarget. 2015 Nov 24;6(37):39891-907. doi: 10.18632/oncotarget.5359.

8.

INPP4B is an oncogenic regulator in human colon cancer.

Guo ST, Chi MN, Yang RH, Guo XY, Zan LK, Wang CY, Xi YF, Jin L, Croft A, Tseng HY, Yan XG, Farrelly M, Wang FH, Lai F, Wang JF, Li YP, Ackland S, Scott R, Agoulnik IU, Hondermarck H, Thorne RF, Liu T, Zhang XD, Jiang CC.

Oncogene. 2016 Jun 9;35(23):3049-61. doi: 10.1038/onc.2015.361.

9.

FAT1 cadherin acts upstream of Hippo signalling through TAZ to regulate neuronal differentiation.

Ahmed AF, de Bock CE, Lincz LF, Pundavela J, Zouikr I, Sontag E, Hondermarck H, Thorne RF.

Cell Mol Life Sci. 2015 Dec;72(23):4653-69. doi: 10.1007/s00018-015-1955-6.

PMID:
26104008
10.

Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis.

Dun MD, Chalkley RJ, Faulkner S, Keene S, Avery-Kiejda KA, Scott RJ, Falkenby LG, Cairns MJ, Larsen MR, Bradshaw RA, Hondermarck H.

Mol Cell Proteomics. 2015 Sep;14(9):2316-30. doi: 10.1074/mcp.M114.046110.

11.

Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer.

Pundavela J, Roselli S, Faulkner S, Attia J, Scott RJ, Thorne RF, Forbes JF, Bradshaw RA, Walker MM, Jobling P, Hondermarck H.

Mol Oncol. 2015 Oct;9(8):1626-35. doi: 10.1016/j.molonc.2015.05.001.

12.

Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion.

Roselli S, Pundavela J, Demont Y, Faulkner S, Keene S, Attia J, Jiang CC, Zhang XD, Walker MM, Hondermarck H.

Oncotarget. 2015 Apr 30;6(12):10473-86.

13.

Docosahexaenoic acid inhibits the invasion of MDA-MB-231 breast cancer cells through upregulation of cytokeratin-1.

Blanckaert V, Kerviel V, Lépinay A, Joubert-Durigneux V, Hondermarck H, Chénais B.

Int J Oncol. 2015;46(6):2649-55. doi: 10.3892/ijo.2015.2936.

PMID:
25825023
14.

Nerve-Cancer Cell Cross-talk: A Novel Promoter of Tumor Progression.

Jobling P, Pundavela J, Oliveira SM, Roselli S, Walker MM, Hondermarck H.

Cancer Res. 2015 May 1;75(9):1777-81. doi: 10.1158/0008-5472.CAN-14-3180. Review.

15.

Proteogenomics: emergence and promise.

Faulkner S, Dun MD, Hondermarck H.

Cell Mol Life Sci. 2015 Mar;72(5):953-7. doi: 10.1007/s00018-015-1837-y.

PMID:
25609363
16.

NGF and ProNGF: Regulation of neuronal and neoplastic responses through receptor signaling.

Bradshaw RA, Pundavela J, Biarc J, Chalkley RJ, Burlingame AL, Hondermarck H.

Adv Biol Regul. 2015 May;58:16-27. doi: 10.1016/j.jbior.2014.11.003. Review.

17.

ProNGF correlates with Gleason score and is a potential driver of nerve infiltration in prostate cancer.

Pundavela J, Demont Y, Jobling P, Lincz LF, Roselli S, Thorne RF, Bond D, Bradshaw RA, Walker MM, Hondermarck H.

Am J Pathol. 2014 Dec;184(12):3156-62. doi: 10.1016/j.ajpath.2014.08.009.

PMID:
25285721
18.

Antiproliferative and apoptotic effects of the oxidative dimerization product of methyl caffeate on human breast cancer cells.

Bailly F, Toillon RA, Tomavo O, Jouy N, Hondermarck H, Cotelle P.

Bioorg Med Chem Lett. 2013 Jan 15;23(2):574-8. doi: 10.1016/j.bmcl.2012.11.009.

PMID:
23228470
19.

Neurotrophins and their receptors in breast cancer.

Hondermarck H.

Cytokine Growth Factor Rev. 2012 Dec;23(6):357-65. doi: 10.1016/j.cytogfr.2012.06.004. Review.

PMID:
22749855
20.

Proteome changes induced by overexpression of the p75 neurotrophin receptor (p75NTR) in breast cancer cells.

Wilmet JP, Tastet C, Desruelles E, Ziental-Gelus N, Blanckaert V, Hondermarck H, Le Bourhis X.

Int J Dev Biol. 2011;55(7-9):801-9. doi: 10.1387/ijdb.113345jw.

Items per page

Supplemental Content

Loading ...
Support Center